An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

The EU has approved an injectable HIV drug offering a two-month dosage schedule, marking a breakthrough in treatment ...

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...